RenewalBio, a spin-out from Professor Jacob Hanna’s lab at the Weizmann Institute, develops a novel bio-manufacturing platform using stembroids—lab-grown embryo-like models derived from human pluripotent stem cells. By cultivating these structures up to day 14, RenewalBio harnesses natural differentiation to produce young, patient-matched blood cells intended for bone marrow failure therapy, potentially advancing regenerative transplantation and longevity applications.

Key points

• Generation of human stembroids from pluripotent stem cells mimics day 14 embryonic development.
• Production of autologous young blood cells targets bone marrow failure without donor dependence.
• Platform yields multiple cell types—endothelial, neuronal, pancreatic, liver—for broad regenerative applications.

Why it matters: This stembroid-based method establishes a scalable, patient-specific source of high-quality cells, promising safer and more effective regenerative therapies.